We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Merus Nv
5 own
7 watching
Current Price
$54.25
$-0.07
(-0.14%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
3,243.49M
52-Week High
61.61000
52-Week Low
19.80500
Average Volume
0.26M
Dividend Yield
--
P/E Ratio
--
Market Capitalization3,243.49M52-Week High61.6100052-Week Low19.80500Average Volume0.26MDividend Yield--P/E Ratio--What does the Merus Nv do?
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Read More
How much money does Merus Nv make?
News & Events about Merus Nv.
Globe Newswire
1 year ago
- 37% overall response rate (ORR) observed in 43 evaluable patients- 6 months median duration of response as of Feb. 1, 2023 data cutoff date- End-of-phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in HNSCC- Investor call on April 17, 2023 at 6:30 p...
Globe Newswire
1 year ago
- Robust 36% overall response rate (ORR) in 42 evaluable patients - 6 months median duration of response with 17 patients still on treatment as of Nov. 28, 2022 data cutoff - End-of-Phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in HNSCC - Investor...
Globe Newswire
1 year ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced the publication of ...
Globe Newswire
1 year ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., President, Chief Executive ...
Globe Newswire
1 year ago
- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (NRG1+) cancer have been treated with zenocutuzumab (Zeno) monotherapy - Petosemtamab clinical update planned for first half of 2023 - MCLA-129 clinical update planned for second half of 2023 - Based on the Companys current...
Frequently Asked Questions
Frequently Asked Questions
What is Merus Nv share price today?
Can Indians buy Merus Nv shares?
How can I buy Merus Nv shares from India?
Can Fractional shares of Merus Nv be purchased?
What are the documents required to start investing in Merus Nv stocks?
What is today’s traded volume of Merus Nv?
What is today’s market capitalisation of Merus Nv?
What is the 52-Week High and Low Range of Merus Nv?
What percentage is Merus Nv down from its 52-Week High?
What percentage is Merus Nv up from its 52-Week Low?
Current Price
$54.25
$-0.07
(-0.14%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.